Fibrosing interstitial lung diseases: knowns and unknowns

Vincent Cottin 1, Lutz Wollin2, Aryeh Fischer3, Manuel Quaresma2, Susanne Stowasser2 and Sergio Harari4

Affiliations: 1National Reference Centre for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, Claude Bernard University Lyon 1, Lyon, France. 2Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany. 3Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado School of Medicine, Denver, CO, USA. 4Division of Pulmonary and Critical Care Medicine, San Giuseppe Hospital MultiMedica IRCCS, Milan, Italy.

Correspondence: Vincent Cottin, Hôpital Louis Pradel, Service de Pneumologie, 28 Avenue Doyen Lepine, 69677 Lyon, France. E-mail: vincent.cottin@chu-lyon.fr

Patients with certain types of fibrosing interstitial lung disease are at risk of developing a progressive phenotype characterised by self-sustaining fibrosis, decline in lung function, worsening quality of life, and early mortality.

Cite this article as: Cottin V, Wollin L, Fischer A, et al. Fibrosing interstitial lung diseases: knowns and unknowns. Eur Respir Rev 2019; 28: 180100 [https://doi.org/10.1183/16000617.0100-2018].

ABSTRACT

Patients with certain types of fibrosing interstitial lung disease (ILD) are at risk of developing a progressive phenotype characterised by self-sustaining fibrosis, decline in lung function, worsening quality of life, and early mortality. It has been proposed that such progressive fibrosing ILDs, which show commonalities in clinical behaviour and in the pathogenetic mechanisms that drive progressive fibrosis, may be “lumped” together for the purposes of clinical research and, potentially, for treatment. At present, no drugs are approved for the treatment of ILDs other than nintedanib and pirfenidone for the treatment of idiopathic pulmonary fibrosis. For other progressive fibrosing ILDs, the mainstay of drug therapy is immunosuppression. However, it is postulated that, once the response to lung injury in fibrosing ILDs has reached the stage at which fibrosis has become progressive and self-sustaining, targeted antifibrotic therapy would be required to slow disease progression. Nintedanib, an intracellular inhibitor of tyrosine kinases, has shown antifibrotic, anti-inflammatory and vascular remodelling effects in several non-clinical models of fibrosis, irrespective of the trigger for the injury. Ongoing clinical trials will provide insight into the role of antifibrotic treatment with nintedanib or pirfenidone in the management of fibrosing ILDs with a progressive phenotype.

Introduction

Interstitial lung disease (ILD) encompasses a large and heterogeneous group of parenchymal lung disorders, which overlap in their clinical presentations and patterns of lung injury. ILDs include several diseases of unknown cause [1], as well as ILDs known to be related to other diseases or to environmental exposures. One of the most common types of ILD is idiopathic pulmonary fibrosis (IPF). IPF is, by definition, a progressive fibrosing ILD characterised by decline in lung function and early mortality [2]. Patients with certain other types of chronic fibrosing ILD are also at risk of developing a progressive phenotype. These include idiopathic nonspecific interstitial pneumonia (NSIP) [3], unclassifiable idiopathic interstitial pneumonia [4], autoimmune ILDs [5], chronic sarcoidosis [6], chronic hypersensitivity pneumonitis (HP) [7] and exposure-related diseases such as asbestosis and silicosis [8].
It has been proposed that, for the purposes of clinical research and, potentially, for treatment, IPF be “lumped” with other forms of fibrosing ILD that have similar biological and clinical behaviours, i.e. self-sustaining fibrosis, progressive decline in lung function, and early mortality [9, 10]. The terminology “progressive fibrosing ILDs” has been coined to describe ILD in patients who, independent of the classification of the ILD, at some point in time exhibit a progressive fibrosing phenotype.

In this article, we review key knowns and unknowns related to the chronic fibrosing ILDs that may have a progressive phenotype (figure 2). This review is based on a symposium held at the European Respiratory Society International Congress in September 2017.

Defining progression in patients with fibrosing ILDs

End-points in clinical trials
Progression of fibrosing ILDs is reflected in an increase in fibrosis evident on a computed tomography scan, a decline in forced vital capacity (FVC) and gas exchange (i.e. diffusing capacity of the lung for carbon monoxide (DLco)), worsening of symptoms and exercise capacity, and deterioration in health-related quality of life. There is no consensus as to how disease progression should be defined in patients with ILDs. Most clinical trials and observational studies in patients with ILDs have defined disease progression in terms of decline in FVC, measured as the change from baseline in mL or as a percentage of the predicted value, or as a categorical change (typically ≥10% predicted), or as a composite of categorical change and mortality. In patients with IPF, decline in FVC is a well-established predictor of mortality [11, 12]. In a retrospective analysis of data from 1132 patients with IPF who received placebo in the TOMORROW, INPULSIS, CAPACITY and ASCEND trials, patients who had an absolute FVC decline of 10–15% predicted had a more than two-fold greater risk of mortality compared with those with an absolute FVC decline of <5% predicted (hazard ratio (HR) 2.20, 95% CI 1.10–4.37) [12]. Acute deteriorations in respiratory function accompanied by evidence of new abnormalities on imaging (known as acute exacerbations) are believed to be a reflection of disease progression. In patients with IPF, acute exacerbations are associated with very high mortality [13, 14]. In the retrospective analysis of data from
the TOMORROW, INPULSIS, CAPACITY and ASCEND trials, having an acute exacerbation was associated with a HR for mortality of 10.3 [12]. Respiratory-related hospitalisations, which capture most acute exacerbations, appear to be associated with an even higher risk of mortality [12].

In addition to lung function parameters, several other end-points have been used to assess disease progression in clinical trials in IPF (table 1). All these end-points have value in assessing the effects of patient characteristics and interventions on disease progression in patients with ILDs, but they do not always reflect the outcomes that are most relevant to patients. Patients are more concerned about the impact that their disease has on their daily lives and fear hospitalisations and the initiation of oxygen therapy. The use of long-term oxygen therapy to alleviate breathlessness and hypoxaemia in patients with ILDs is likely to indicate that lung function impairment has progressed to a severe stage and is associated with a large increase in the risk of mortality [15, 16].

**Assessing progression in clinical practice**

In clinical practice, progression of ILD is typically monitored through pulmonary function tests, evaluation of symptoms, and, less frequently, by chest imaging. In-clinic measurements of FVC are essential to monitor how a patient’s disease is progressing, but are limited by the test variability and, potentially, by confounding effects of comorbidities such as emphysema. Furthermore, previous decline in FVC is not a good predictor of future decline in FVC. In an analysis of FVC measurements from two databases, of 50 patients with IPP who had a decline in FVC of $\geq 10\%$ predicted during year 1, 84% had stable FVC over year 2; of 135 patients who had stable FVC during year 1, 19% had a decline in FVC of $\geq 10\%$ predicted during year 2 [17]. Similarly, a pooled analysis of data from the ASCEND and CAPACITY trials found only a weak negative correlation between changes in FVC in two consecutive 6-month intervals [18]. Weekly or even daily measurement of FVC using home spirometry may provide a more accurate picture of disease behaviour and enable therapeutic decisions to be made more swiftly [19, 20].

**TABLE 1 End-points used in clinical trials to assess disease progression in idiopathic pulmonary fibrosis**

| Lung function | Rate of decline in FVC (mL·year$^{-1}$)  
|               | Absolute or relative changes in FVC (mL or % predicted)  
|               | Absolute or relative changes in DLCO % predicted  
|               | Categorical declines in FVC or DLCO (mL or % predicted)  
| Exercise capacity | Absolute change in 6-min walk test distance  
|                  | Categorical decline in 6-min walk test distance  
|                  | Change in oxygen saturation nadir during 6-min walk test  
| Patient-reported outcomes | Open question(s) on symptoms  
|                         | St George’s Respiratory Questionnaire (SGRQ)  
|                         | University of California San Diego Shortness of Breath Questionnaire (UCSD-SOBQ)  
|                         | Cough and Sputum Assessment Questionnaire (CASA-Q)  
|                         | EuroQol 5-Dimensional Quality of Life Questionnaire (EQ-5D)  
|                         | Short-Form Health Survey (SF-36)  
| Acute worsenings | Acute exacerbations  
|                 | Respiratory hospitalisations  
|                 | All-cause hospitalisations  
| Mortality | All-cause mortality  
|           | Death due to respiratory cause  
|           | Progression-free survival  
| Radiological markers | Quantitative fibrosis scores based on HRCT  
| Serum biomarkers | Krebs von den Lungen-6 protein (KL-6)  
|                  | Surfactant proteins D and A  
|                  | Neoeptopes (biomarkers of extracellular matrix turnover)  

FVC: forced vital capacity; DLCO: diffusing capacity of the lung for carbon monoxide; HRCT: high-resolution computed tomography.
Although several studies have identified predictors of disease progression in patients with ILDs, the course of disease for an individual patient remains impossible to predict. This creates a huge challenge in defining treatment response in patients with progressive disease, as disease progression does not necessarily equal treatment failure. There is great interest in applying the concept of precision medicine to ILDs. Identification of patient subgroups based on genetic or molecular profiles, or on environmental or behavioural factors, may enable better prediction of the course of disease for individual patients and facilitate the selection of therapies that are most likely to be effective in those patients [10, 21–23].

In the following sections, we will focus on autoimmune ILDs and chronic HP as examples of chronic ILDs that may develop a progressive phenotype.

**Autoimmune ILDs**

Autoimmune diseases are commonly associated with pulmonary complications including ILD [5]. Patients across the spectrum of connective tissue diseases (CTDs) are at risk of developing ILD, including those with systemic sclerosis (SSc) [24]; rheumatoid arthritis (RA) [25]; inflammatory myopathies such as polymyositis, dermatomyositis and anti-synthetase syndrome [26, 27]; and Sjögren’s syndrome [28]. A further group of patients develops interstitial pneumonia with features suggestive of an autoimmune disease that do not meet criteria for a defined disease. The term ‘interstitial pneumonia with autoimmune features’ (IPAF) has been proposed to describe this constellation [29]. Discussion continues as to how patients with IPAF should be classified and managed in clinical practice [30, 31].

**Systemic sclerosis**

ILD associated with autoimmune disease is particularly common in patients with SSc. ILD tends to occur early in the course of SSc. In an analysis of 695 patients with SSc in the EUSTAR database, approximately one third of patients developed DLCO <50% predicted within 3 months of the onset of Raynaud’s phenomenon [32]. ILD is one of the leading causes of death related to SSc [33, 34]. A greater extent of fibrosis on a high-resolution computed tomography (HRCT) scan is highly predictive of mortality: in a seminal study, the risk of mortality was over three times greater (HR 3.46) in patients with extensive fibrosis on HRCT and worse lung function (FVC or LCO) have also been shown to be predictors of mortality in patients with RA-ILD [35].

**Rheumatoid arthritis**

The lifetime risk of developing clinically significant ILD in patients with RA is estimated to be 10% and ILD accounts for approximately 7% of RA-related deaths [36]. In a recent study, the MUC5B promoter variant rs35705950, an established genetic risk factor for IPF, was identified as a risk factor for RA-ILD, particularly RA-ILD with a usual interstitial pneumonia (UIP) pattern on HRCT [37]. RA-ILD has a variable clinical course but may result in severe impairment in lung function [38]. In a retrospective study of 167 patients with RA-ILD treated at a single centre, the proportion of patients with FVC <50% predicted rose from 14% at diagnosis to 22% at 5 years, while the proportion of patients with DLCO <40% predicted rose from 29% at diagnosis to 40% at 5 years. Patients with a UIP pattern on HRCT, who comprised 53% of the patients in this study, were more likely to progress to DLCO <40% predicted than those with NSIP [39]. In a retrospective review of hospital records from 84 patients with RA-ILD and UIP, after a median of 33 months, one third of patients had experienced a decline in FVC of >10% predicted and/or a decline in DLCO of >15% predicted, and 17% had experienced an acute exacerbation [40]. The presence of a UIP pattern also confers a worse prognosis than other patterns on HRCT in patients with IPAF [41] and unclassifiable ILD [42]. In a study of data from 144 patients with IPAF in a US registry, patients with a UIP pattern had similar survival to patients with IPF, while those with IPAF and patterns other than UIP had a similar survival to patients with CTD-ILDs [41]. A greater extent of fibrosis on HRCT and worse lung function (FVC or DLCO) have also been shown to be predictors of mortality in patients with RA-ILD [43, 44].

**Treatment**

No drugs are licensed for the treatment of ILDs related to autoimmune diseases. Treatment guidelines issued by the European League Against Rheumatism (EULAR) recommend tailored therapy with cyclophosphamide (CYC) for SSc-ILD, in particular for patients with progressive ILD [45, 46]. This recommendation was made based on the results of two randomised controlled trials [47, 48]. In the Fibrosing Alveolitis in Scleroderma Trial (FAST), 45 patients with SSc and pulmonary fibrosis received oral prednisolone on alternate days plus monthly intravenous infusions of CYC for 6 months followed by oral azathioprine for 6 months, or placebo for 12 months [47]. There was an improvement of 2.4% in FVC % predicted with active treatment versus a decline of 3.0% with placebo (p=0.08), but 32% and 43% of patients in these groups, respectively, withdrew prior to month 12 [47]. In the Scleroderma Lung Study
Other than for SSc-ILD, there are no data from randomised controlled trials to inform treatment decisions in patients with autoimmune ILDs and no treatment guidelines issued by a professional association. Treatment of autoimmune ILDs usually involves corticosteroids or other immunosuppressants such as azathioprine, CYC or MMF, based on clinical experience rather than scientific evidence. Corticosteroids are usually given as first-line therapy but should not be used at a dose above 15 mg·day$^{-1}$ in patients with SSc and are not a viable option for long-term treatment. Biological therapies such as rituximab [50, 51] have shown positive effects on lung function in some studies in patients with autoimmune ILDs, but are not approved for the treatment of ILD. Non-drug approaches such as pulmonary rehabilitation, supplemental oxygen and supportive care are important elements of the overall care of patients with autoimmune ILDs, as is the management of extrapulmonary manifestations of disease and comorbidities. Patient monitoring should include longitudinal assessments of FVC, DLCO, symptoms, exercise capacity and HRCT scans, in addition to a careful assessment of medication tolerance. In most cases, stability of these factors may be considered a successful outcome.

The role of antifibrotic drugs shown to slow disease progression in patients with IPF [52, 53] in patients with other forms of fibrosing ILD remains to be determined, but several trials are ongoing, including trials of nintedanib in patients with SSc-ILD (NCT02597933) and in patients with progressive fibrosing ILDs other than IPF (NCT02999178) and trials of pirfenidone in patients with RA-ILD (NCT02808871), progressive unclassifiable ILD (NCT03099187) [54], and as add-on to MMF (versus MMF alone) in patients with SSc-ILD (NCT03221257). In future, if trials of antifibrotic therapies are positive, the treatment of fibrosing autoimmune ILDs might involve both immunosuppression and antifibrotic therapy.

Chronic hypersensitivity pneumonitis

HP is a complex syndrome caused by sensitisation to an inhaled antigen that leads to an aberrant immune response in the small airways and lung parenchyma. Susceptibility is believed to be affected by genetics, antigen concentration and frequency of exposure, and immune tolerance [55]. Even in the context of multidisciplinary teams (MDTs), making a diagnosis of HP is challenging due to the difficulty in identifying causative antigens, variability in the patterns observed on HRCT and histopathology, overlap in presentation between HP and other ILDs, and the lack of a standardised diagnostic algorithm. In an analysis of inter-MDT agreement for the diagnosis of ILDs, the weighted kappa value for diagnosis of HP (indicating the level of agreement) was 0.29 (interquartile range (IQR) 0.24–0.40), compared with 0.73 (IQR 0.64–0.77) for IPF [56]. In a prospective case–cohort study at a single centre, of 46 patients diagnosed with IPF, 20 were diagnosed with chronic HP after additional testing [57].

Some patients with acute HP go on to develop chronic HP, and some of these patients develop a progressive fibrosing phenotype [58, 59]. Several studies have demonstrated that fibrosis on HRCT or biopsy is associated with worse survival in patients with HP [7, 60–62]. In a retrospective study of 142 patients with chronic HP, patients with fibrosis on HRCT and surgical lung biopsy had a median survival of 4.9 years, compared with 16.9 years in those without fibrosis. An inability to identify the inciting antigen, older age, lower FVC % predicted and a history of smoking were also predictive of mortality [7]. As in IPF, the single nucleotide polymorphism MUC5B rs35705950 and short telomere length have been associated with reduced survival in patients with chronic HP [63].

There is no established treatment algorithm for HP and a poor evidence base to inform therapeutic decision-making. Management of HP typically involves removal of the antigen (if it can be identified) and the use of corticosteroids or other immunosuppressants, despite very limited evidence to support their efficacy [58, 59, 64]. As such, much remains unknown regarding the treatment of patients with chronic HP, including the risks and benefits of immunosuppression and antifibrotic therapies.

Nintedanib as a potential treatment for chronic fibrosing ILDs with a progressive phenotype

Nintedanib is a tyrosine kinase inhibitor that targets receptors including the platelet-derived growth factor receptor α and β, fibroblast growth factor receptor 1–3, and vascular endothelial growth factor receptor 1–3, as well as the non-receptor Src family kinase Lck (lymphocyte-specific tyrosine-protein kinase) and...
the colony-stimulating factor 1 receptor [65, 66]. Experiments conducted in vitro in human cells with relevance to ILDs have shown that nintedanib inhibits a number of processes involved in the initiation and progression of fibrosis, including pro-fibrotic mediator release [67]; M2 macrophage differentiation [68, 69]; the migration and differentiation of fibrocytes [70]; the proliferation, migration and differentiation of fibroblasts [71–74]; and the release of collagen [68, 73, 74]. Data from animal models with features of fibrosing ILDs suggest that nintedanib has antifibrotic and anti-inflammatory effects, irrespective of the trigger that caused the lung injury (table 2) [69, 73, 75–78]. Taken together, these data suggest that nintedanib inhibits processes that are fundamental to the progression of fibrosis.

Clinical trials have demonstrated that nintedanib reduces decline in lung function and the risk of acute exacerbations in patients with IPF with a manageable side-effect profile [52, 79, 80]. Nintedanib has been approved as a treatment for IPF in many countries and received a conditional recommendation for use in the latest international clinical practice guideline for IPF [81]. Similarities in biological and clinical behaviours (i.e. self-sustaining fibrosis, progressive decline in lung function, early mortality), together with the non-clinical data showing that nintedanib has antifibrotic effects irrespective of the trigger, provide a rationale for the investigation of nintedanib as a treatment for chronic fibrosing ILDs other than IPF. It is postulated that, once the response to lung injury in fibrosing ILDs has reached the stage at which fibrosis has become progressive and self-sustaining, targeted antifibrotic therapy would be required to slow disease progression.

The efficacy and safety of nintedanib versus placebo in patients with progressive fibrosing ILDs other than IPF are being investigated in the randomised double-blind INBUILD trial [9]. This trial recruited patients with features of diffuse fibrosing lung disease of >10% extent on an HRCT scan who met criteria for disease progression in the 24 months before screening, based on decline in FVC, worsening of symptoms, or an increased extent of fibrotic changes on chest imaging. Patients who had received (unapproved) medications to treat ILD were eligible to participate if defined washout periods were observed prior to randomisation [9]. The primary end-point is the annual rate of decline in FVC in mL·year$^{-1}$ assessed over 52 weeks. The trial is powered to show a treatment effect in two co-primary analysis populations: all patients and patients with a UIP-like fibrotic pattern on HRCT. Change from baseline in King’s Brief Interstitial Lung Disease Questionnaire (K-BILD) total score at week 52, time to first acute exacerbation of ILD or death over 52 weeks, and time to death over 52 weeks are being assessed as secondary end-points.

In a separate trial, known as the SENSCIS trial, patients with SSc, onset of disease (first non-Raynaud symptom) ≤7 years before screening, and ≥10% fibrosis of the lungs on an HRCT scan have been randomised to receive nintedanib or placebo double-blind for at least 52 weeks [82]. Patients receiving prednisone (≤10 mg·day$^{-1}$) and/or stable background therapy with mycophenolate or methotrexate are eligible to participate. As in the INBUILD trial, the primary end-point is the annual rate of decline in FVC in mL·year$^{-1}$ assessed over 52 weeks. Key secondary end-points in the SENSCIS trial are absolute changes from baseline in modified Rodnan skin score (a measure of skin fibrosis) and in St George’s Respiratory Questionnaire total score at week 52.

Conclusions

IPF is the “prototype” chronic fibrosing ILD with a progressive phenotype as it is, by definition, an ILD associated with progressive pulmonary fibrosis and has no known cause. A proportion of patients with certain other types of chronic fibrosing ILD also develop a progressive phenotype characterised by decline in lung function, worsening quality of life and, ultimately, early mortality. It has been suggested that these diseases may be considered as a group for the purposes of clinical research and, potentially, for treatment. There is no consensus as to how disease progression should be defined in patients with ILDs, but in clinical practice it is typically assessed through assessment of lung function, symptoms, imaging features and clinical events such as acute exacerbations and respiratory hospitalisations. Other than nintedanib and

| Trigger          | Model                                                                 |
|------------------|----------------------------------------------------------------------|
| Chemical         | Bleomycin-induced lung fibrosis [73, 75, 76]                          |
| Environmental    | Silica-induced lung fibrosis [73]                                    |
| Vascular         | Ovalbumin-induced lung fibrosis and remodelling [77]                 |
| Immunological    | Fra-2 transgenic mice [model of systemic sclerosis] [69]             |
|                  | SKG transgenic mice-zymosan [model of RA-ILD] [78]                   |

RA-ILD: rheumatoid arthritis-associated interstitial lung disease.

https://doi.org/10.1183/16000617.0100-2018
pirfenidone for the treatment of IPF, no drugs are approved for the treatment of ILDs and there is a poor evidence base to inform therapeutic decision-making. Non-clinical evidence suggests that nintedanib inhibits fundamental processes in the pathogenesis of fibrosis, irrespective of the trigger. Ongoing clinical trials will provide insight into the role of antifibrotic therapies in the treatment of fibrosing ILDs with a progressive phenotype.

Acknowledgements: Medical writing assistance, supported financially by Boehringer Ingelheim, was provided by Elizabeth Ng and Wendy Morris of FleishmanHillard Fishburn, London, UK, during preparation of this manuscript. The authors were fully responsible for all content and editorial decisions, were involved at all stages of development and have approved the final version.

Conflict of interest: V. Cottin reports personal fees from Actelion (for consultancy, lectures and travel to medical meetings), Boehringer Ingelheim (for development of educational presentations, consultancy, lectures and travel to medical meetings), Bayer (for consultancy), Gilead (as a member of an adjudication committee), MSD (for consultancy and travel to medical meetings), Novartis (for consultancy and lectures), Roche (for consultancy, lectures and travel to medical meetings), Sanofi (for consultancy and lectures), Promedior (as chair of the Data and Safety Monitoring Board (DSMB)), Celgene (for the DSMB) and Galapagos (for consultancy and as chair of the DSMB), as well as grants from Boehringer Ingelheim and Roche to his institution, all outside the submitted work. L. Wollin is an employee of Boehringer Ingelheim International GmbH. A. Fischer reports grants and consultancy fees from Boehringer Ingelheim, and consultancy fees from P. Hoffman La Roche, Bristol-Myers Squibb, GlaxoSmithKline, Pfizer and Genentech, during the conduct of the study; M. Quaresma is an employee of Boehringer Ingelheim International GmbH. S. Stowasser is an employee of Boehringer Ingelheim International GmbH. S. Harari reports grants and personal fees from Roche, Actelion and Boehringer Ingelheim, outside the submitted work. In addition to being investigator in trials involving these companies, relationships include lectures and membership of scientific advisory boards, and grants for research.

Support statement: Funding was received from Boehringer Ingelheim. Funding information for this article has been deposited with the Crossref Funder Registry.

References
1 Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. *Am J Respir Crit Care Med* 2013; 188: 733–748.
2 Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. *Am J Respir Crit Care Med* 2011; 183: 788–824.
3 Belloli EA, Beckford R, Hadley R, et al. Idiopathic non-specific interstitial pneumonia. *Respirology* 2016; 21: 259–268.
4 Hyldgaard C, Bendsrøe E, Wells AU, et al. Unclassifiable interstitial lung diseases: clinical characteristics and survival. *Respirology* 2017; 22: 494–500.
5 Fischer A, Chartrand S. Assessment and management of connective tissue disease-associated interstitial lung disease. *Sarcoidosis Vascul Dis Diffuse Lung Dis* 2015; 32: 2–21.
6 Patterson KC, Strek ME. Pulmonary fibrosis in sarcoidosis. Clinical features and outcomes. *Ann Am Thorac Soc* 2013; 10: 362–370.
7 Fernández Pérez ER, Swigris JJ, Forssén AV, et al. Identifying an inciting antigen is associated with improved survival in patients with chronic hypersensitivity pneumonitis. *Chest* 2013; 144: 1644–1651.
8 Khalil N, Churg A, Muller N, et al. Environmental, inhaled and ingested causes of pulmonary fibrosis. *Toxicol Pathol* 2007; 35: 86–96.
9 Flaherty KR, Brown KK, Wells AU, et al. Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease. *BMJ Open Respir Res* 2017; 4: e000212.
10 Wells AU, Brown KK, Flaherty KR, et al. What’s in a name? That which we call IPF, by any other name would act the same. *Eur Respir J* 2018; 51: 1800092.
11 du Bois RM, Weycker D, Albera C, et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. *Am J Respir Crit Care Med* 2011; 184: 1382–1389.
12 Paterniti MO, Bi Y, Rekić D, et al. Acute exacerbation and decline in forced vital capacity are associated with increased mortality in idiopathic pulmonary fibrosis. *Ann Am Thorac Soc* 2017; 14: 1395–1402.
13 Collard HR, Ryerson CJ, Corte TJ, et al. Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report. *Am J Respir Crit Care Med* 2016; 194: 265–275.
14 Natsuiizaka M, Chiba H, Kuronuma K, et al. Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences. *Am J Respir Crit Care Med* 2014; 190: 773–779.
15 Hook JL, Arcasoy SM, Zemmel D, et al. Titrated oxygen requirement and prognostication in idiopathic pulmonary fibrosis. *Eur Respir J* 2012; 39: 359–365.
16 Sharp C, Adamali HI, Millar AB. A comparison of published multidimensional indices to predict outcome in idiopathic pulmonary fibrosis. *ERJ Open Res* 2017; 3: 00096-2016.
17 Schmidt SL, Tayob N, Han MK, et al. Predicting pulmonary fibrosis disease course from past trends in pulmonary function. *Chest* 2014; 145: 579–585.
18 Nathan SD, Albera C, Bradford WZ, et al. Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis. *Thorax* 2016; 71: 429–435.
19 Russell AM, Adamali HI, Molyneaux PL, et al. Daily home spirometry: an effective tool for detecting progression in idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 2016; 194: 989–997.
20 Johansson KA, Vittinghoff E, Morisset J, et al. Home monitoring improves endpoint efficiency in idiopathic pulmonary fibrosis. *Eur Respir J* 2017; 50: 1602406.
FIBROSING INTERSTITIAL LUNG DISEASES | V. COTTIN ET AL.

21 Maher TM. Beyond the diagnosis of idiopathic pulmonary fibrosis; the growing role of systems biology and stratified medicine. Curr Opin Pulm Med 2013; 19: 460–465.
22 Brownell R, Kaminski N, Woodruff PG, et al. Precision medicine: the new frontier in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2016; 193: 1213–1218.
23 Magnini D, Montemurro G, Iovene B, et al. Idiopathic pulmonary fibrosis: molecular endotypes of fibrosis stratifying existing and emerging therapies. Respiration 2017; 93: 379–395.
24 Solomon JJ, Olson AL, Fischer A, et al. Scleroderma lung disease. Eur Respir Rev 2013; 22: 6–19.
25 Turesson C, O’Fallon WM, Crowson CS, et al. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann Rheum Dis 2003; 62: 722–727.
26 Marie I, Hachulla E, Chérin P, et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 2002; 47: 614–622.
27 Lega JC, Reynaud Q, Belot A, et al. Idiopathic inflammatory myopathies and the lung. Eur Respir Rev 2015; 24: 216–238.
28 Nannini C, Jебакумар Aj, Crowson CS, et al. Primary Sjögren’s syndrome 1976–2005 and associated interstitial lung disease: a population-based study of incidence and mortality. BMJ Open 2013; 3: e003569.
29 Fischer A, Antoniou KM, Brown KK, et al. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimnune features. Eur Respir J 2015; 46: 976–987.
30 Sambataro G, Sambataro D, Torrisi SE, et al. State of the art in interstitial pneumonia with autoimmune features: a systematic review on retrospective studies and suggestions for further advances. Eur Respir Rev 2018; 27: 170139.
31 Cavagna L, Gonzalez Gay MA, Allanore Y, et al. Interstitial lung disease with autoimmune features: a new classification still on the move. Eur Respir Rev 2018; 27: 180047.
32 Jaeger VK, Wirz EG, Allanore Y, et al. Incidences and risk factors of organ manifestations in the early course of systemic sclerosis: a longitudinal EUSTAR study. PLoS One 2016; 11: e0163894.
33 Tyn dall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69: 1809–1815.
34 Elhai M, Meune C, Boubaya M, et al. Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis 2017; 76: 1897–1905.
35 Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008; 177: 1248–1254.
36 Olson AL, Swigris JJ, Sprunger DB, et al. Rheumatoid arthritis-Interstitial lung disease-associated mortality. Am J Respir Crit Care Med 2011; 183: 372–378.
37 Juge PA, Lee JS, Ebstein E, et al. MUC5B promoter variant and rheumatoid arthritis with interstitial lung disease. N Engl J Med 2018; 379: 2209–2219.
38 Spagnolo P, Lee JS, Sverzellati N, et al. The lung in rheumatoid arthritis: focus on interstitial lung disease. Arthritis Rheumatol 2018; 70: 1544–1554.
39 Zamora-Legoff JA, Krause ML, Crowson CS, et al. Progressive decline of lung function in rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheumatol 2017; 69: 542–549.
40 Song JW, Lee HK, Lee CK, et al. Clinical course and outcome of rheumatoid arthritis-associated usual interstitial pneumonitis. Sarcoïdosis Vasc Diffuse Lung Dis 2013; 30: 103–112.
41 Oldham JM, Adegunsoye A, Valenzi E, et al. Characterisation of patients with interstitial pneumonia with autoimmune features. Eur Respir J 2016; 47: 1767–1775.
42 Ryerson CJ, Urbania TH, Richeldi L, et al. Prevalence and prognosis of unclassifiable interstitial lung disease. Eur Respir J 2013; 42: 750–757.
43 Assayag D, Lubin M, Lee JS, et al. Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease. Respir Med 2014; 19: 493–500.
44 Solomon JJ, Chung JH, Cosgrove GP, et al. Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J 2016; 47: 588–596.
45 Kowal-Bielecka O, Landewé R, Avouac J, et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009; 68: 620–628.
46 Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 2017; 76: 1327–1339.
47 Hoyles RK, Ellis RW, Wellsbury J, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheumatol 2006; 54: 3962–3970.
48 Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 2655–2666.
49 Tashkin DP, Both MD, Clements PJ, et al. Mucypenolone mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 2016; 4: 708–719.
50 Sircar G, Goswami RP, Sircar D, et al. Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial. Rheumatology 2018; 57: 2106–2113.
51 Doyle TJ, Dhillon N, Madan R, et al. Rituximab in the treatment of interstitial lung disease associated with antisyntehetase syndrome: a multicenter retrospective case review. J Rheumatol 2018; 45: 841–850.
52 Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071–2082.
53 King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2083–2092.
54 Maher TM, Corle TJ, Fischer A, et al. Pirfenidone in patients with unclassifiable progressive fibrotic interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial. BMJ Open Respir Res 2018; 5: e000289.
55 Selman M, Pardo A, King TE Jr. Hypersensitivity pneumonitis: insights in diagnosis and pathobiology. Am J Respir Crit Care Med 2012; 186: 314–324.
56 Walsh SLF, Wells AU, Desai SR, et al. Multicentre evaluation of multidisciplinary team meeting agreement on diagnosis in diffuse parenchymal lung disease: a case-cohort study. Lancet Respir Med 2016; 4: 557–565.

https://doi.org/10.1183/16000617.0100-2018
Tandon K, Herrmann FE, Ayaub E, Wollin L, Ostermann A, Williams C. Nintedanib inhibits pro-fibrotic mediators from T cells with relevance to Hilberg F, Tontsch-Grunt U, Baum A, Ley B, Newton CA, Arnould I, Hilberg F, Roth GJ, Krssak M, Wang P, Jones KD, Urisman A, Morisset J, Johannson KA, Vittinghoff E, et al. Use of mycophenolate mofetil or azathioprine for the management of chronic hypersensitivity pneumonia. Chest 2017; 151: 619–625.

Hilberg F, Roth GJ, Krsak M, et al. BIRF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008; 68: 4774–4782.

Hilberg F, Tontsch-Grunt U, Baum A, et al. Triple angiokinase inhibitor nintedanib directly inhibits tumor cell growth and induces tumor shrinkage via blocking oncogenic receptor tyrosine kinases. J Pharmacol Exp Ther 2018; 364: 494–503.

Wollin L, Ostermann A, Williams C. Nintedanib inhibits pro-fibrotic mediators from T cells with relevance to connective tissue disease-associated interstitial lung disease. Eur Respir J 2017; 50: Suppl. 61, PA903.

Tandem K, Herrmann FE, Ayaub E, et al. Nintedanib attenuates the polarization of profibrotic macrophages through the inhibition of tyrosine phosphorylation on CSF1 receptor. Am J Respir Crit Care Med 2017; 195: A2397.

Huang J, Maier C, Zhang Y, et al. Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis. Ann Rheum Dis 2017; 76: 1941–1948.

Sato S, Shinohara S, Hayashi S, et al. Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity. Respir Res 2018; 19: 172.

Hostettler KE, Zhong J, Papakonstantinou E, et al. Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis. Respir Res 2014; 5: 157.

Wollin L, Ostermann A, Wex E, et al. Nintedanib attenuates motility of lung fibroblasts from patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2014; 189: A2008.

Wollin L, Wex E, Pauthsch A, et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J 2015; 45: 1434–1445.

Huang J, Beyer C, Palumbo-Zerr K, et al. Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis. Ann Rheum Dis 2016; 75: 883–890.

Wollin L, Maillet I, Quesniaux V, et al. Anti-fibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. J Pharmacol Exp Ther 2014; 349: 209–220.

Ackermann M, Kim YO, Wagner WL, et al. Effects of nintedanib on the microvascular architecture in a lung fibrosis model. Angiogenesis 2017; 20: 359–372.

Lee HY, Hur J, Kim IK, et al. Effect of nintedanib on airway inflammation and remodeling in a murine chronic asthma model. Exp Lung Res 2017; 43: 187–196.

Redente EF, Aguilar MÁ, Black BP, et al. Nintedanib reduces pulmonary fibrosis in a model of rheumatoid arthritis-associated interstitial lung disease. Am J Physiol Lung Cell Mol Physiol 2018; 314: L998–L1009.

Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011; 365: 1079–1087.

Richeldi L, Cottin V, du Bois RM, et al. Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS trials. Respir Med 2016; 113: 74–79.

Raghu G, Rochwerg B, Zhang Y, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med 2015; 192: e3–e19.

Distler O, Brown KK, Distler JHW, et al. Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENCSIS). Clin Exp Rheumatol 2017; 35: Suppl. 106, 75–81.